By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
Bimatoprost is a drug used to treat high pressure inside the eye, including glaucoma, and is marketed under the trade name Lumigan among others.
It is used specifically for open-angle glaucoma when other treatments are insufficient. The length of the eyelashes can also be increased with this method.
It is administered as an eye drop, and effects often start to show within four hours. Red eyes, dry eyes, changing eye color, hazy vision, and cataracts are typical side effects.
It is generally not advised to use during pregnancy or breastfeeding. It is a prostaglandin analog that works by causing the eyes to produce more aqueous fluid. In the US, bimatoprost has received approval for medicinal usage. It is accessible as a generic drug.
With more than 3 million prescriptions written, it was the 166th most often prescribed medication in the US.
Adults with open-angle glaucoma and ocular hypertension are treated with bimatoprost alone or in conjunction with a beta blocker, usually timolol.
The prostaglandin analogs latanoprost and travoprost, as well as bimatoprost, are at least as effective as timolol in lowering intraocular pressure (IOP). Treatment for short or undeveloped eyelashes with bimatoprost is an option.
The FDA has approved this for solely aesthetic uses only, despite the fact that the medical word for this is the therapy of hypotrichosis (see Prostaglandin F receptor#Clinical relevance).
When administered to the eye, prostaglandin analogs have comparable side effects. Conjunctival hyperemia, which affects more than 10% of patients, is the most typical.
Vision blur, eye and eyelid redness, eye burning or other irritation, and a persistent browning of the iris are potential side effects. Headache and nausea are rare side effects that occur in less than 1% of people.
The cosmetic product’s side effects are unique since it is applied to the skin near the base of the eyelash rather than injected into the eye, and so only affects that area of the body.
If the single-use applicators are re-used, they include infection and darkening of the eyelid or the area under the eye. In comparison to not wiping off excess fluid, using an absorbent pad to wipe the eye after applying eye drops can lead to shorter eyelashes and a lower risk of hyperpigmentation in the eyelid.
The Global BIMATOPROST market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
The U.S. Food and Drug Administration (FDA) has approved Allergan plc’s New Drug Application (NDA) for Bimatoprost Sustained-Release, the company’s more than 70-year-old flagship in the field of eye care (SR).
If approved, the sustained-release, biodegradable implant known as bimatoprost SR would be the first of its kind for treating primary open-angle glaucoma or ocular hypertension in patients.
